Abstract
With recent guidelines emphasizing patient values, patient preferences and shared decision-making in regards to prostate specific antigen (PSA) screening it is important for primary care providers and urologists to identify factors that influence men's decisions to undergo PSA screening. We sought to evaluate the impact of men's perceptions of healthcare quality on obtaining a screening PSA for the early detection of prostate cancer. A retrospective secondary data analysis was conducted of men ages 55–69 without a history of prostate cancer using 2015 Medical Expenditure Panel Survey (MEPS) data. The relationship between Consumer Assessment of Healthcare Providers and Systems (CAHPS) questions captured in MEPS and PSA screening in the last two years were assessed using multiple logistic regression. The analysis was carried out in October 2018 at Dartmouth-Hitchcock Medical Center. The final survey sample consisted of 1249 men that equated to 15,313,605.5 once weighted; 69.5% underwent PSA screening. Men who were offered help with filling out forms in the office (OR: 1.86, 95% CI: 1.14–3.01) or rated the quality of healthcare from their doctors ≥7 (OR: 1.63, 95% CI: 1.10–2.44) on a scale from 0 (worst healthcare) to 10 (best health care) had significantly greater adjusted odds of undergoing PSA screening. Men who rated the quality of healthcare delivered to them as high had significantly greater odds of undergoing PSA screening compared to those who rated it lower. Our results may suggest that improvements in healthcare quality and patient experience of care have the potential to positively influence PSA screening.
Highlights
The use of prostate specific antigen (PSA) screening for the early detection of prostate cancer remains controversial
Limited evidence exists regarding how healthcare quality may influence men's decisions to pursue PSA screening. The purpose of this analysis was to evaluate the impact of men's perceptions of healthcare quality on PSA screening for the early detection of prostate cancer
The survey sample consisted of 1249 men that equated to 15,313,605.5 weighted individuals; 69.5% of these men underwent PSA screening in the last two years
Summary
The use of prostate specific antigen (PSA) screening for the early detection of prostate cancer remains controversial. The American Urological Association and United States Preventive Services Task Force currently recommend shared decision-making for men ages 55 to 69 who are considering PSA screening and proceeding based on a patient's values and clinical circumstances (U.S Preventive Services Task Force, 2018; American Urological Association, 2018). In this conversation, the benefits of reducing metastatic prostate cancer diagnoses and prostate cancer-specific mortality are weighed against the potential harms of over-diagnosis and treatment (Aus et al, 2007; Loeb et al, 2014). The purpose of this analysis was to evaluate the impact of men's perceptions of healthcare quality on PSA screening for the early detection of prostate cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
